British drugmaker GSK said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main ...

The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...

The NDA includes a combination of Blenrep with bortezomib plus dexamethasone (BorDex) or pomalidomide plus dexamethasone ...

Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...

The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. The company's product portfolio includes prescription medicines and ...

GSK Says mRNA Flu Shot Shows Promise in Boost for Pipeline GSK could beat Pfizer to market, says chief commercial officer Several drugmakers are betting on mRNA seasonal flu vaccines ...

GSK has turned to Brooke Shields to get the message out about shingles vaccination. The drugmaker has worked with the model and actor to talk to female celebrities and patients aged 50 years and ...

In a report released today, Peter Welford from Jefferies maintained a Buy rating on GlaxoSmithKline (GSK – Research Report), with a price ...

After an initial defeat against the biggest barrier to mRNA flu vaccines—namely, B strains of influenza—GSK has returned with a reformulated candidate that has delivered the goods in the all ...

GSK Plc shares rose on Wednesday, buoyed by a US court’s decision to review whether evidence supporting claims that heartburn drug Zantac causes cancer is scientifically sound. The British ...